GNI Group Ltd.

Tokyo Stock Exchange 2160.T

GNI Group Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 25.42%

GNI Group Ltd. Return on Capital Employed (ROCE) is 25.42% for the year ending December 31, 2023, a 371.92% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

GNI Group Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 5.39%, a -14.81% change year over year.
GNI Group Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 6.32%, a -43.42% change year over year.
GNI Group Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 11.18%, a 53.77% change year over year.
GNI Group Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 7.27%, a 184.12% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Tokyo Stock Exchange: 2160.T

GNI Group Ltd.

CEO	Dr. Ying Luo Ph.D.
IPO Date	Aug. 31, 2007
Location	Japan
Headquarters	Nihonbashi-Honcho YS Building
Employees	843
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Composite Materials Plastics Tobacco

Description

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years